参芪扶正注射液联合化疗治疗晚期乳腺癌30例临床观察

目的 观察参芪扶正注射液联合化疗治疗晚期乳腺癌的临床疗效。方法 将60例患者采用数字表法随机分为治疗组(30例)与对照组(30例)。两组均采用相同的CTF方案化疗，21天为1个周期，2个周期评价疗效；治疗组同时加用参芪扶正注射液治疗。观察近期疗效、中医证候变化、生活质量变化、不良反应及免疫功能变化等。结果 治疗组与对照组近期总缓解率分别为500%、43.3%(P＞0.05)；临床证候改善率治疗组与对照组分别为700%、46.7%(P＜0.05)；生活质量改善率治疗组与对照组分别为76.7%、50.0%(P＜0.05)；不良反应治疗组发生低于对照组(P＜0.05)；治疗组治疗后CD⁺₃、CD⁺₄及CD⁺₄/CD⁺₈上升(P＜0.05)，CD⁺₈下降(P＜0.01)；对照组治疗前后无明显变化。结论 参芪扶正注射液能减轻化疗造成的骨髓抑制，可通过调节细胞免疫功能增强疗效，改善临床症状，提高生活质量，延长生存期。

Effect of Shenqi Fuzheng Injection Combined with Chemotherapy on Thirty Patients with Advanced Breast Cancer

OBJECTIVE: To observe the clinical efficacy of Shenqi Fuzheng Injection (SFI) combined with chemotherapy in treating patients with advanced breast cancer. METHODS: Sixty patients were randomly assigned to two groups by digital table, the control group and the treatment group, 30 in each group. All patients were treated with the same CTF regimen of chemotherapy for 21 days as one therapeutic cycle, while those in the treatment group were given SFI additionally in the meanwhite. The therapeutic efficacy was evaluated after 2 cycles of treatment by observing the changes of short-term efficacy, TCM syndrome, quality of life and immune function, as well as the adverse reaction. RESULTS: The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05). The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05). The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group. CONCLUSION: For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.